Notably, CLL cells with elevated levels of BCL-XL and MCL-1 are more resistant to venetoclax, with BCL-XL exerting a more dominant influence on this resistance [64], which may be overcome by introducing inhibitors targeting these two proteins, achieving synergy with venetoclax. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.